

## **Expert insights on biomarker testing in advanced personalized NSCLC care**

### **Chair**

Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

### **Faculty**

Xiuning Le, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Zofia Piotrowska, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

**Release date: November 30, 2022**

**Expiration date: November 30, 2023**

**Estimated time to completion: 1.25 hour**

**Available CME credits: 1.25 AMA PRA Category 1 Credit(s)<sup>™</sup>**

### **Activity description**

This activity will provide: a thorough understanding of the clinical utility of diverse advanced molecular diagnostic techniques at different moments during the patient's treatment journey; acknowledgement of clinically relevant targetable oncogenic drivers; and practical insights on the implementation of personalized treatment strategies, including the use of novel targeted therapies.

The activity consists of 3 elements: 3 interactive e-learning modules narrated by the expert faculty; a webcast including patient cases presented by the experts; and a supporting practice guide, to inform and inspire improvements in patient care.

### **Target audience**

This activity is intended for oncologists, pulmonologists, pathologists, surgeons, nurses, pharmacists, and all healthcare professionals (HCPs) engaged in the diagnosis and care of patients with non-small-cell lung cancer (NSCLC).

### **Educational objectives**

After completing this activity, the participant should be better able to:

- Discuss the clinical value of rare oncogenic biomarkers (including *MET*ex14 and *MET* amplification) and the rationale behind the clinical recommendations for molecular profiling
- Integrate advanced molecular diagnostic techniques throughout the management of NSCLC
- Implement personalized treatment strategies into clinical practice, including use of targeted therapies and disease management, based on biomarker assessment

### **Joint accreditation statement**

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

### **Physician continuing medical education**

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Method of participation and request for credit**

There are no fees for participating in, and receiving CME/CE credit for, this activity.

In order to claim credit, participants must complete the following procedures during the period November 30, 2022, through November 30, 2023:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. Complete the webcast, the 3 interactive e-learning and the clinical practice guide
3. Take the post-activity test and complete the evaluation
4. Indicate the number of credits earned and download the certificate of CME credit

### **Disclosure of conflicts of interest**

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty	Relationship identified with:
Stephen Liu	<p>Consultant/Advisory Board: Amgen, AstraZeneca, Bayer, Beigene, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, Merck/MSD, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics.</p> <p>Research grant (to institution): Alkermes, Blueprint Medicines, Bristol Myers Squibb, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, Pfizer, RAPT Therapeutics, Turning Point Therapeutics.</p>
Xiuning Le	<p>Grant/Research Support: Boehringer Ingelheim, Eli Lilly, EMD Serono, Regeneron.</p> <p>Consultant/Advisory Board: AbbVie, AstraZeneca, Boehringer Ingelheim, Eli Lilly, EMD Serono (Merck KGaA), Jiangsu Hengrui Pharmaceuticals, Janssen, Novartis, Spectrum Pharmaceuticals.</p>
Zofia Piotrowska	<p>Grant/Research Support: AbbVie, AstraZeneca, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Spectrum Pharmaceuticals, Takeda, Tesaro/GSK.</p> <p>Consultant/Advisory Board: AstraZeneca, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo, Eli Lilly, Jazz Pharmaceuticals, Janssen, Takeda.</p>

### Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

### Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.

### **Financial support**

This activity is supported by an independent educational grant from EMD Serono.

### **Disclosure of unlabeled use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### **Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

### **Contact information for questions about the activity**

Elena Knoche, Senior Medical Communications Manager

[info@ologyeducation.org](mailto:info@ologyeducation.org), [www.ologyeducation.org](http://www.ologyeducation.org)

Chantel Crowl, Program Manager

[inquiries@pimed.com](mailto:inquiries@pimed.com), [www.pimed.com](http://www.pimed.com)

### **System requirements**

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

**Policy on Privacy and Confidentiality**

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

**Media**

Internet